Hydrocortisone
- Generic Name
- Hydrocortisone
- Brand Names
- Ala-cort, Ala-scalp, Alcortin, Alkindi, Anusol HC, Aquanil HC, Casporyn HC, Cipro, Cipro HC, Colocort, Cortaid, Cortane-B, Cortef, Cortenema, Cortisporin, Cortizone-10, Dermacort, Dermarest Eczema, Dermazene, Home Papkit, Hydroskin, Monistat Itch Relief, Neosporin Eczema, Preparation H Hydrocortisone, Procto-med, Procto-pak, Proctocort, Proctol, Proctosedyl, Proctosol, Proctozone HC, Scalpicin Itch Relief, Texacort, Vanoxide-HC, Xerese, Plenadren, Efmody
- Drug Type
- Small Molecule
- Chemical Formula
- C21H30O5
- CAS Number
- 50-23-7
- Unique Ingredient Identifier
- WI4X0X7BPJ
- Background
Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions. It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone.
Hydrocortisone was granted FDA approval on 5 August 1952.
- Indication
Otic solutions are indicated for infections of the external auditory canal caused by susceptible organisms and with inflammation. Hydrocortisone tablets are indicated for certain endocrine, rheumatic, collagen, allergic, ophthalmic, respiratory, hematologic, neoplastic, edematous, gastrointestinal, and other conditions. A hydrocortisone enema is indicated for ulcerative colitis, a topical ointment with antibiotics is indicated for corticosteroid responsive dermatoses with infections, and a topical cream with acyclovir is indicated to treat cold sores. Oral granules of hydrocortisone are used as a replacement therapy for Adrenocortical Insufficiency (AI) in children under 17 years of age.
- Associated Conditions
- Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Adrenal Insufficiency, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Crohn's Disease (CD), Dermatitis, Dermatomyositis (DM), Dermatosis, Drug hypersensitivity reaction, Epicondylitis, Erythroblastopenia, Fissure;Anal, Haemorrhoids, Herpes Labialis, Hypercalcemia of Malignancy, Immune Thrombocytopenia (ITP), Infection of the Fenestration Cavity, Infection of the Mastoidectomy Cavity, Iridocyclitis, Iritis, Itching caused by Hemorrhoids, Itching of the Anus, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Lymphomas NEC, Mycosis Fungoides (MF), Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Hemorrhoids, Pemphigus, Posterior Uveitis, Posttraumatic Osteoarthritis, Primary adrenocortical insufficiency, Proctitis, Proteinuria, Pruritis of the skin, Psoriatic Arthritis, Rectal inflammations NEC, Rheumatic heart disease, unspecified, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Skin Diseases, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Trichinosis, Tuberculous Meningitis, Ulcerative Colitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Tenosynovitis, Acute rheumatic carditis, Anterior eye segment inflammation, Cryptitis, Disseminated Pulmonary Tuberculosis (TB), Exfoliative erythroderma, Fulminating Pulmonary Tuberculosis, Non-suppurative Thyroiditis, Severe Erythema multiforme, Severe Psoriasis, Subacute Bursitis, Superficial infection of the external auditory canal with inflammation, Symptomatic Sarcoidosis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis
- Associated Therapies
- Palliative Treatment
Tolerability and Acceptance of Two Oral Hydrocortisone Compounding Formulation for Pediatrics
- Conditions
- Adrenal Insufficiency
- Interventions
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2024-05-30
- Target Recruit Count
- 35
- Registration Number
- NCT06435481
- Locations
- 🇪🇸
Hospital Universitari Vall d'Hebron, Barcelona, Spain
Cannabinoids and Biological Reactivity to Stress
- Conditions
- Cannabis Use Disorder
- Interventions
- First Posted Date
- 2024-05-28
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- Auburn University
- Target Recruit Count
- 36
- Registration Number
- NCT06430580
- Locations
- 🇺🇸
Auburn University BRAINS Lab, Auburn, Alabama, United States
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
- Conditions
- T-cell LymphomaT-cell Acute Lymphoblastic LeukemiaMixed Phenotype Acute Leukemia
- Interventions
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT06390319
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Bayesian Basket Trial
- Conditions
- Sepsis
- Interventions
- Drug: Low molecular weight heparinDrug: Recombinant humanThrombomodulin( rhTM)Biological: Fresh frozen plasmaOther: Usual care
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 2000
- Registration Number
- NCT06381661
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Conditions
- B Acute Lymphoblastic LeukemiaAcute Leukemia of Ambiguous Lineage
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Computed TomographyProcedure: Echocardiography TestProcedure: FDG-Positron Emission TomographyProcedure: Lumbar PunctureProcedure: Magnetic Resonance ImagingProcedure: Multigated Acquisition Scan
- First Posted Date
- 2024-03-19
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 153
- Registration Number
- NCT06317662
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸Albany Medical Center, Albany, New York, United States
🇺🇸University of Virginia Cancer Center, Charlottesville, Virginia, United States
Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
- Conditions
- Lymphoblastic LymphomaMixed Phenotype Acute LeukemiaAcute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2024-03-04
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 850
- Registration Number
- NCT06289673
- Locations
- 🇺🇸
United States, Tennessee St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Effects of Steroid Replacement Therapy on Metabolic, Cardiovascular and Bone Outcomes in Adrenal Insufficiency
- Conditions
- Adrenal Insufficiency
- Interventions
- Drug: Conventional glucocortidois
- First Posted Date
- 2024-02-15
- Last Posted Date
- 2024-02-15
- Lead Sponsor
- University of Palermo
- Target Recruit Count
- 88
- Registration Number
- NCT06260462
Early Intravenous Hydrocortisone in Sepsis
- Conditions
- Sepsis SevereShock, Septic
- Interventions
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Siriraj Hospital
- Target Recruit Count
- 230
- Registration Number
- NCT06217939
- Locations
- 🇹🇭
Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkoknoi, Bangkok, Thailand
A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)
- Conditions
- Prostatic NeoplasmsMetastatic Castration-Resistant Prostate Cancer
- Interventions
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 14
- Registration Number
- NCT06136598
- Locations
- 🇨🇳
Peking University First Hospital-Urology ( Site 0001), Beijing, Beijing, China
🇨🇳Tongji Hospital Tongji Medical,Science & Technology ( Site 0002), Wuhan, Hubei, China
🇨🇳Sun Yat-sen University Cancer Center-Neurosurgery department ( Site 0003), Guangzhou, Guangdong, China
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- Conditions
- Prostatic NeoplasmsMetastatic Castration-resistant Prostate Cancer (mCRPC)
- Interventions
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1500
- Registration Number
- NCT06136650
- Locations
- 🇺🇸
The University of Arizona Cancer Center - North Campus ( Site 0073), Tucson, Arizona, United States
🇺🇸UCLA Hematology/Oncology - Santa Monica ( Site 0044), Los Angeles, California, United States
🇺🇸University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0040), Orange, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.